MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Applied Therapeutics

Applied Therapeutics Announces Key Leadership Appointments
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Reports First Quarter 2025 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT RVPH VSTM
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Reports Third Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics to Participate in Upcoming Investor Conferences
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Reports Second Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Added to Russell 3000® Index
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Reports First Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Announces $100 Million Private Placement
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics Reports Third Quarter 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
From Applied Therapeutics
Via GlobeNewswire
Tickers APLT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story